Tyra Biosciences drew attention at the IBCG26 retreat with new research in intermediate-risk non-muscle invasive bladder cancer, adding momentum to its SURF302 trial and broader targeted therapy pipeline.
published
Tyra Biosciences drew attention at the IBCG26 retreat with new research in intermediate-risk non-muscle invasive bladder cancer, adding momentum to its SURF302 trial and broader targeted therapy pipeline.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.